inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study: * diagnosed sars-cov-2+ status. either became symptomatic in the prior 7 days, or if not symptomatic, likely infected/exposed within the prior 7 days. all patients listed from the university of north carolina at chapel hill (unc) respiratory diagnostic center (rdc) have a confirmed sars-cov-2 infection and have consented to be contacted for research purposes. for patients contacting study coordinators for enrollment, who were not tested in the rdc, they must provide written proof of positive sars-cov-2 status in the prior 7 days. * individuals (all sex, all gender) at least 18 years of age and at most 65 years of age and in good oral health without any known allergies to commercial dental products or cosmetics. american society of anaesthesiologists (asa) class i or ii prior to sars-cov-2 infection. * evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial and all of their questions have been answered. * able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based on research site personnel's assessment. * females of childbearing potential will have a negative urine pregnancy test (on site) or be physically incapable of pregnancy (implants or injections, intrauterine device, bilateral tubal ligation, hysterectomy, ovariectomy, women post-menopausal)

inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study: * diagnosed sars-cov-2+ status. either became symptomatic in the prior 7 days, or if not symptomatic, likely infected/exposed within the prior 7 days. all patients listed from the university of north carolina at chapel hill (unc) respiratory diagnostic center (rdc) have a confirmed sars-cov-2 infection and have consented to be contacted for research purposes. for patients contacting study coordinators for enrollment, who were not tested in the rdc, they must provide written proof of positive sars-cov-2 status in the prior 7 days. * individuals (all sex, all gender) at least 18 years of age and at most 65 years of age and in good oral health without any known allergies to commercial dental products or cosmetics. american society of anaesthesiologists (asa) class i or ii prior to sars-cov-2 infection. * evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial and all of their questions have been answered. * able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based on research site personnel's assessment. * females of childbearing potential will have a negative urine pregnancy test (on site) or be physically incapable of pregnancy (implants or injections, intrauterine device, bilateral tubal ligation, hysterectomy, ovariectomy, women post-menopausal)

inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study: - diagnosed sars-cov-2+ status. either became symptomatic in the prior 7 days, or if not symptomatic, likely infected/exposed within the prior 7 days. all patients listed from the university of north carolina at chapel hill (unc) respiratory diagnostic center (rdc) have a confirmed sars-cov-2 infection and have consented to be contacted for research purposes. for patients contacting study coordinators for enrollment, who were not tested in the rdc, they must provide written proof of positive sars-cov-2 status in the prior 7 days. - individuals (all sex, all gender) at least 18 years of age and at most 65 years of age and in good oral health without any known allergies to commercial dental products or cosmetics. american society of anaesthesiologists (asa) class i or ii prior to sars-cov-2 infection. - evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial and all of their questions have been answered. - able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based on research site personnel's assessment. - females of childbearing potential will have a negative urine pregnancy test (on site) or be physically incapable of pregnancy (implants or injections, intrauterine device, bilateral tubal ligation, hysterectomy, ovariectomy, women post-menopausal)

inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study: - diagnosed sars-cov-2+ status. either became symptomatic in the prior 7 days, or if not symptomatic, likely infected/exposed within the prior 7 days. all patients listed from the university of north carolina at chapel hill (unc) respiratory diagnostic center (rdc) have a confirmed sars-cov-2 infection and have consented to be contacted for research purposes. for patients contacting study coordinators for enrollment, who were not tested in the rdc, they must provide written proof of positive sars-cov-2 status in the prior 7 days. - individuals (all sex, all gender) at least 18 years of age and at most 65 years of age and in good oral health without any known allergies to commercial dental products or cosmetics. american society of anaesthesiologists (asa) class i or ii prior to sars-cov-2 infection. - evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial and all of their questions have been answered. - able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based on research site personnel's assessment. - females of childbearing potential will have a negative urine pregnancy test (on site) or be physically incapable of pregnancy (implants or injections, intrauterine device, bilateral tubal ligation, hysterectomy, ovariectomy, women post-menopausal)